Biology of the VEGF family of angiogenic growth factors Roles of the VEGF family in pregnancy Roles of the VEGF family in adverse pregnancy outcomes VEGF family gene polymorphisms and adverse pregnancy outcomes † Discussion background: Pre-eclampsia, small-for-gestational-age infants, preterm birth and recurrent miscarriage complicate a significant number of pregnancies. The vascular endothelial growth factor (VEGF) family of angiogenic growth factors is implicated in the pathophysiology of these complications. We aimed to elucidate the role of these angiogenic factors in placentation and to evaluate the predictive value of their protein concentrations and genetic variations in pregnancy complications.
Introduction
Pre-eclampsia, small-for-gestational age (SGA) pregnancy, preterm birth and recurrent miscarriage together complicate 17 -29% of all pregnancies (Li et al., 2002; Sibai, 2003; Sibai et al., 2005; Goldenberg et al., 2008) . Defects in early placentation processes, including trophoblast invasion, spiral artery remodelling and angiogenesis are implicated in the pathogenesis of these complications (Khong et al., 1986; Kim et al., 2002 Kim et al., , 2003 Mayhew et al., 2004; Ball et al., 2006a, b) . The vascular endothelial growth factor (VEGF) family of angiogenic growth factors are important molecules regulating early placental vascular changes. The key molecules VEGF-A and placental growth factor (PlGF) and the receptors VEGF receptor 1 (fms-like-tyrosine-kinase receptor 1, FLT-1) and VEGF receptor 2 (kinase insert domain receptor, KDR) are expressed in the human placenta throughout gestation, and the VEGF family is known to regulate placental angiogenesis and maternal spiral artery remodelling (Senger et al., 1996; Charnock-Jones et al., 2004) . In addition to the two main membrane-bound receptors, a splice variant of FLT-1 designated soluble FLT-1 (sFLT-1) is expressed in the placenta and is known to have potent anti-angiogenic properties. Soluble FLT-1 antagonises both VEGF-A and PlGF and induces symptoms of pre-eclampsia in animal models (Maynard et al., 2003) .
In humans, placental expression and maternal serum concentrations of sFLT-1 are up-regulated, and maternal serum-free VEGF-A and PlGF are reduced, in preeclamptic women compared with normotensive pregnant women. Consistent evidence exists that these changes are detected several weeks prior to the clinical onset of symptoms of preeclampsia . Therefore, sFLT-1 and PlGF are considered as biomarkers in predicting pre-eclampsia early in pregnancy.
Although these biomarkers in combination with other clinical and biochemical markers are demonstrated to have a strong predictive value for early onset (and consequently severe) pre-eclampsia, their value in predicting the more common late onset disease is questionable.
These biomarkers are also not restricted to pre-eclampsia, as several groups have shown their involvement in pregnancies to be complicated by small-for-gestational-age infants and to a lesser extent, in the pathophysiology of preterm birth and recurrent miscarriage.
This review examines the role of VEGF family angiogenic growth factors in placentation and the implications of derangements in these molecules in the development of pre-eclampsia, as well as pregnancies complicated by small-for-gestational-age infants, preterm birth and recurrent miscarriage. We also evaluate the role of VEGF family proteins, as well as their genetic variations, in predicting these pregnancy complications.
Methods
An extensive online search of published articles on the VEGF family in normal and complicated pregnancy was undertaken. We used the Pubmed database employing combinations of the following search terms: pregnancy, VEGF, PlGF, FLT-1, KDR, sFLT-1, placenta, trophoblast invasion, spiral artery remodelling, angiogenesis, vascularization, preeclampsia, small-for-gestational-age infants, preterm birth, recurrent pregnancy loss, single nucleotide polymorphism, biomarker and prediction. The search was mainly focused on publications involving humans, but experimental studies with animals or cell culture models were included where appropriate. In addition, references cited in the selected articles and reviews were searched. Only articles written in English were considered. The review was conducted according to the roles of the VEGF family in placental development including trophoblast invasion and spiral artery remodelling, vascularization and implantation and their roles in pregnancy complications classified as pre-eclampsia, SGA pregnancy, preterm birth and recurrent pregnancy loss. Finally, we reviewed articles on polymorphisms in VEGF family genes in pregnancy complications.
Results

Biology of the VEGF family of angiogenic growth factors
The VEGF family (see Fig. 1 ) consists of VEGF-A, PlGF, VEGF-B, VEGF-C and VEGF-D as wells as their receptors VEGFR-1 (also called FLT-1), VEGFR-2 (also called KDR, in humans and fetal liver kinase, Flk, in mice; Waltenberger et al., 1994) and , as well as the co-receptors, neuropilin-1 (NRP-1) and NRP-2.
Vascular endothelial growth factor-A
The human VEGF-A gene has been assigned to chromosome 6p12-p21.1 (Mattei et al., 1996) and is organized as eight exons separated by seven introns . VEGF-A binds with high affinity to two related receptor tyrosine kinases expressed on vascular endothelial cells (de Vries et al., 1992; Terman et al., 1992) , FLT-1 and KDR (Waltenberger et al., 1994) . In addition, VEGF-A also binds to NRP-1 and NRP-2.
VEGF-A mediates many functions in endothelial cells. VEGF-A promotes angiogenesis, induces the growth of vascular endothelial cells (Ferrara and Davis-Smyth, 1997) , reduces apoptosis (Zhou et al., 2003) , mediated via the KDR/Flk1 receptor through the PI3-kinase/ Akt signal transduction pathway (Gerber et al., 1998) , and increases vascular permeability (Dvorak et al., 1995) . In addition, VEGF-A promotes vasodilatation via the endothelial-derived nitric oxide pathway. Hypoxia is a potent stimulus for the expression of VEGF-A mRNA and is mediated via hypoxia-inducible-factor-1a (Taylor et al., 1997; Semenza 2002 ). In addition, several growth factors including fibroblast growth factor, transforming growth factors (TGF-a and TGF-b), keratinocyte growth factor, insulin-like growth factor 1 (IGF-1) and platelet-derived growth factor, as well as the inflammatory cytokines, interleukin (IL)-1a and IL-6, are also known to up-regulate VEGF-A expression (Ferrara and Davis-Smyth, 1997; Neufeld et al., 1999) .
Placental growth factor
PlGF demonstrates 42% amino acid sequence identity with VEGF-A (de Falco et al., 2002) . PlGF has been assigned to human chromosome 14 and consists of seven exons (Maglione et al., 1993) . Alternative mRNA splicing of the PlGF primary transcript results in four isoforms, PlGF-1 (PlGF 131 ), PlGF-2 (PlGF 152 ), ) and PlGF-4 (PlGF 224 ) (Maglione et al., 1993) differing in secretion properties and binding affinities (Ribatti, 2008) . PlGF homodimers bind FLT-1 and NRP-1 while PlGF/VEGF-A heterodimers bind KDR and FLT-1/ KDR heterodimers in vitro. PlGF is predominantly expressed in the placenta, heart and lungs. The exact physiological actions of PlGF are still not clear, however, evidence suggests a pivotal role for PlGF in regulating VEGF-dependent angiogenesis under pathological conditions (Carmeliet et al., 2001) . A few proposed mechanisms by which PlGF potentiates angiogenesis are by (i) stimulating endothelial cells via FLT-1, (ii) separating VEGF-A from FLT-1, allowing VEGF-A to activate KDR, (iii) recruiting monocytes/macrophages which have a crucial role in vessel growth (Ribatti, 2008) and (iv) inducing the secretion of VEGF-A from monocytes .
Vascular endothelial growth factor-B
VEGF-B has structural similarities to VEGF-A and PlGF, and VEGF-B gene is localized to chromosome 11q13 (Paavonen et al., 1996) . It is expressed as two isoforms VEGF-B 167 and VEGF-B 186, and is abundant in heart and skeletal muscle (Olofsson et al., 1996a, b) . VEGF-B forms stable heterodimers with VEGF-A (Olofsson et al., 1996a, b) and is generally co-expressed with VEGF-A. VEGF-B binds to two of the VEGF receptors, FLT-1 (Olofsson et al., 1998) and NRP-1 (Makinen et al., 1999) . VEGF-B is reported to behave as an endothelial cell mitogen (Olofsson et al., 1996a, b) but part of the mitogenic activity may be due to VEGF-A/VEGF-B heterodimers.
Vascular endothelial growth factor-C VEGF-C has been recognized as a lymphatic system regulator during embryogenesis as well as in adult life, and the VEGF-C gene is localized to chromosome 4q34 (Paavonen et al., 1996) . VEGF-C has a high affinity for both KDR and FLT-4 (Joukov et al., 1996) . VEGF-C induces selective lymphangiogenesis without accompanying angiogenesis and is mainly expressed together with FLT-4 predominantly in regions where lymphatic vessels develop.
Vascular endothelial growth factor-D
VEGF-D is also a primarily lymphangiogenic growth factor and the VEGF-D gene has been localized to chromosome Xp22.31 (Tammela et al., 2005) . VEGF-D binds to both KDR and FLT-4 and is present in many human tissues, most abundantly in skin and lung during embryogenesis. Although mainly a mediator of lymphangiogenesis, animal experiments have shown VEGF-D to possess strong angiogenic properties (Rissanen et al., 2003) .
Fms-like tyrosine kinase receptor-1
Fms-like tyrosine kinase receptor (FLT-1) is composed of seven extracellular immunoglobulin homology domains, a single transmembrane region and an intracellular tyrosine kinase sequence that is interrupted by a kinase-insert domain (Shibuya et al., 1990) . The FLT-1 gene is localized to chromosomes 13q12-q13 (Tammela et al., 2005) . FLT-1 binds VEGF-A, VEGF-B and PlGF with high affinity and is expressed in many human tissues including monocytes/macrophages and placental trophoblasts, and its expression is up-regulated by hypoxia (Gerber et al., 1997) .
Alternative splicing of the pre-mRNA which encodes FLT-1 results in the production of sFLT-1 comprising the ligand-binding domain of FLT-1 but lacking the membrane-spanning and intracellular domains (He et al., 1999) . Soluble FLT-1 is secreted by endothelial cells, monocytes and the placenta (Shibuya, 2006) . Soluble FLT-1 acts as a potent antagonist of VEGF-A and PlGF, by inhibiting their binding to cell surface receptors (Kendall and Thomas, 1993) as well as by forming heterodimers with KDR (Kendall et al., 1996) , and is considered an anti-angiogenic factor. Recently, a human-specific splice variant of FLT-1 was discovered to produce a soluble receptor designated sFLT-14 (Sela et al., 2008) . Soluble FLT-14 is primarily expressed in non-endothelial cells, notably vascular smooth muscle cells. Placental expression of the two isoforms of sFLT changes over time with sFLT-1 being the dominant form during the first trimester to almost exclusive sFLT-14 production by term. Major sites of placental sFLT-14 expression are degenerative syncytiotrophoblasts known as syncytial knots. Soluble FLT-14 is qualitatively different from sFLT-1, but is a potent inhibitor of VEGF-A signalling, with its inhibitory activity being comparable to that of sFLT-1 (Sela et al., 2008) .
Kinase insert domain receptor
KDR has a structure similar to FLT-1 and the KDR gene is localized to chromosomes 4q11-q12 (Tammela et al., 2005) . KDR binds VEGF-A, VEGF-C and VEGF-D. Although the binding affinity of VEGF-A for KDR is lower than that of FLT-1, it has been shown that KDR is the primary receptor transmitting VEGF-A signals in endothelial cells (Gille et al., 2001) . Despite this, other cell types including neuronal cells and megakaryocytes also express KDR. The expression of KDR is auto-regulated, being up-regulated by VEGF-A, VEGF-C and VEGF-D.
A soluble form of the KDR receptor has also been detected in human plasma and is suggested to be secreted by endothelial cells (Ebos et al., 2004) . Alternative mRNA splicing or proteolytic cleavage of the membrane-bound receptor is hypothesized as the probable mechanism of generation of this receptor, but the mechanism remains to be elucidated (Ebos et al., 2004) . Soluble KDR is also considered an anti-angiogenic protein (Maynard et al., 2003) , but its mechanism of action remains unclear.
Fms-like tyrosine kinase-4
FLT-4 has only six immunoglobulin-like domains and the FLT4 gene is localized to chromosomes 5q33-qter (Tammela et al., 2005) . FLT-4 binds VEGF-C and VEGF-D. FLT-4 is present on all endothelia during development, but becomes restricted to lymphatic endothelial cells and certain fenestrated vascular endothelial cells in adult life (Kaipainen et al., 1995; Partanen et al., 2000) .
NRP-1 and NRP-2
NRP-1 binds VEGF-A, VEGF-B and PlGF while NRP-2 binds VEGF-A, VEGF-C and PlGF (Klagsbrun et al., 2002) . In endothelial cells, NRPs are thought to increase VEGF signalling by ensuring optimal presentation of ligands to the receptors and by stabilizing VEGF/VEGFR complexes. Interaction of VEGF-A with NRP-1 is required for VEGF-A binding to KDR, activation of KDR and the downstream signalling and biological actions. Similarly, interaction of VEGF-A or VEGF-C with NRP-2 increases the phosphorylation threshold of KDR and promotes endothelial cell survival and motility (Sulpice et al., 2008) .
Roles of the VEGF family in pregnancy
The VEGF family and implantation Successful implantation depends on the development of healthy functional embryos during the preimplantation period. VEGF-A mRNA expression is detected from the unfertilized oocyte to the blastocyst stage and VEGF-A protein is detected from the 3-cell stage to the blastocyst stage in human embryos (Hwu et al., 2006) , but knowledge on the role of VEGF family in preimplantation embryos is at present limited. A recent study of porcine preimplantation embryos demonstrated that VEGF-A mRNA was expressed in oocytes, 2, 4 and 8-cell embryos, morulae and blastocyst and that KDR and FLT1 mRNA were expressed from the 1-cell to the blastocyst stage (Biswas et al., 2011) . VEGF-A expression has also been shown to be up-regulated in Day 6 rabbit blastocysts (Saenz-de-Juano et al., 2011) . VEGF-A supplementation during porcine and bovine embryonic development is known to improve the rate of blastocyst formation (Einspanier et al., 2002; Biswas et al., 2011) and the blastocyst cell number (Biswas et al., 2011) . As there is no angiogenesis occurring in the early embryos, these findings suggest that VEGF-A may regulate functions other than angiogenesis during the preimplantation period that need to be further explored. Since VEGF-A is known for its role in increasing vascular permeability, it is possible that in the early embryos it may be involved in fluid transport.
Implantation is the complex process where the developing embryo establishes contact with the maternal endometrium initiating the development of the placenta. Endometrial VEGF-A is also likely to be a critical molecule regulating implantation (Smith, 2000) . The most frequently expressed VEGF-A splice variants VEGF-A 121 and VEGF-A 165 are expressed in the endometrium . Uterine expression of VEGF-A appears to be cycle dependant, with increased levels of both VEGF-A mRNA and protein levels reported during the mid-secretory period (Shifren et al., 1996; Torry et al., 1996) . In contrast, increased mid-secretory VEGF-A expression is not evident in women experiencing repeated IVF failures (Jee et al., 2009) suggesting that VEGF-A may have a role in successful implantation. In support of this hypothesis, Hannan and colleagues recently demonstrated that VEGF-A levels were significantly reduced in uterine fluid during the mid-secretory phase in women with unexplained infertility compared with fertile women. They also demonstrated that culturing mouse embryos with either mid-secretory phase uterine fluid from fertile women or recombinant human VEGF-A enhanced blastocyst outgrowth, and that treatment of human endometrial epithelial cells with uterine fluid from fertile women or recombinant human VEGF-A increased endometrial epithelial cell adhesion (Hannan et al., 2011) . These findings suggest novel mechanisms by which VEGF-A may regulate implantation.
The VEGF family and the placenta During pregnancy, the placenta expresses the VEGF family angiogenic growth factors, but the literature is somewhat controversial. While some report that VEGF-A mRNA is expressed in villous and extravillous trophoblasts (EVTs), Hofbauer cells and maternal decidual cells Jackson et al., 1994; Clark et al., 1996; Khaliq et al., 1996; Schiessl et al., 2008) throughout pregnancy, others report that the expression is seen in villous mesenchyme, decidual macrophages and decidual glands but not in trophoblasts (Vuorela et al., 1997; Clark et al., 1998) . In the first trimester of pregnancy, PlGF is mainly expressed in EVT cells within the maternal decidua, but towards term the expression is shown to be abundant in villous trophoblasts (Khaliq et al., 1996; Vuorela et al., 1997; Clark et al., 1998) . The inconsistent results on VEGF-A expression are attributed to the probes used in in situ hybridization studies that may cross-react with PlGF in the trophoblast layer resulting in false-positive results (Clark et al., 1998) . The expression pattern of FLT-1 is similar to that of VEGF-A while abundant KDR expression is localized to areas of endothelial cells (Ahmed et al., 1995; Clark et al., 1996) . These findings suggest that VEGF-A and PlGF may have vital roles in the development of the placental vasculature. At present, data on the expression and function of the other members of the VEGF family on pregnancy and placentation are limited. Recently, it was shown that VEGF-C is expressed in all EVT populations and that VEGF-D is expressed in trophoblasts, decidual stromal cells, endothelial cells and vascular smooth muscle cells of spiral arteries . However, their role in placentation is yet to be determined. Additionally, uterine natural killer cells (NK cells) express high levels of mRNAs for VEGF-C and PlGF while their expression of VEGF-A has been demonstrated to be low Lash et al., 2006) .
Regulation of placental vasculogenesis and angiogenesis
Vasculogenesis and angiogenesis are two processes which are essential in the establishment of the utero-placental circulation. Human placental vascular development begins as early as 21 days post-conception by the formation of haemangioblastic cords and is observed at the stage of early tertiary chorionic villi (Demir et al., 1989) . The initial period of vasculogenesis is followed by a phase of branching angiogenesis (Day 32 to week 25 post conception) during which the haemangioblastic cords develop into a richly branched capillary bed . Placental expressions of VEGF-A, FLT-1 and KDR are intense and the expression of PlGF is moderate during this period . It has been shown that during the organization of the first vessels, angiogenic factors required for the commencement of angiogenesis are supplied by the cytotrophoblast cells, and that as pregnancy advances and villous maturation occurs, additional VEGF-A is supplied by stromal cells including Hofbauer cells (fetal placental macrophages) (Demir et al., 2004 (Demir et al., , 2006 . In vitro experiments on the chorioallantoic membrane of the chick have shown that binding of VEGF-A to FLT-1 and KDR stimulate branching angiogenesis (Wilting et al., 1996) .
From 25 weeks of gestation onwards, angiogenesis switches from branching to non-branching and is accompanied by a decline in VEGF-A and KDR and an increase in the expression of PlGF, FLT-1 and sFLT-1. PlGF, which is expressed in trophoblasts throughout gestation by acting on FLT-1, may, in early gestation, have a supplementary role in vasculogenesis and branching angiogenesis by recruiting macrophages, and from then onwards, it may have a role in the regulation of non-branching angiogenesis which continues to term.
Regulation of trophoblast invasion and spiral artery remodelling
During normal development of the placenta, EVT cells invade the uterine decidua, the inner third of the myometrium (interstitial invasion) and the spiral arteries (endovascular invasion). The process of trophoblast invasion is highly controlled so that the depth of invasion of the uterus is sufficient but not so excessive as to penetrate the myometrium and adjacent organs. For successful invasion, EVT cells need to both increase their motility and secrete specific proteases to break down the extracellular matrix. The urokinase plasminogen activator/ plasminogen pathway and the matrix metalloproteinases play a key role in cellular invasion by degrading the extracellular matrix. In addition to its well-researched action of stimulating endothelial cell proliferation and migration, VEGF-A is known to stimulate metalloproteinase activity of endothelial cells (Wang and Keiser, 1998) . Most in vitro studies have primarily focused on endothelial cells in examining the biologic actions of the VEGF family. The fact that VEGF-A, PlGF and their receptors are expressed in trophoblast cells, which are non-endothelial cells, raises the possibility that VEGF-A and PlGF may exert similar biological actions on the trophoblast cells.
However, in vitro studies to date report results contrary to this hypothesis. One group has shown that VEGF-A and PlGF promote EVT cell proliferation without influencing their migratory or invasive behaviours, while others have shown that VEGF-A and PlGF do not stimulate EVT proliferation (Lash et al., 1999; Fitzpatrick et al., 2003) or invasiveness (Lash et al., 1999; Fitzpatrick et al., 2003) but increase motility of trophoblast cells (Lash et al., 1999 Fitzpatrick et al., 2003) . One study has also shown that VEGF-A inhibits the invasion of first trimester trophoblast cells and decreases the cell surface expression of urokinase plasminogen activator, a molecule required for trophoblast invasion (Fitzpatrick et al., 2003) . This VEGF-A-induced reduction in invasion is inhibited by the addition of a VEGF-A neutralizing antibody (Fitzpatrick et al., 2003) . The results of these in vitro studies could indicate that the increased motility of trophoblast cells in response to VEGF-A may be an initial response to attract trophoblast cells to the decidua, and that VEGF-A may then limit the degree to which the cells invade (Lash et al., 1999) .
During endovascular invasion, the endothelium and the underlying vascular smooth muscle cells are replaced by EVT embedded in a fibrinoid rich matrix (Harris, 2011) . This spiral artery remodelling results in the conversion of narrow-calibre high-resistance vessels into wide-calibre low-resistance vessels capable of supplying enough maternal blood to the placenta to accommodate the increasing demands of the rapidly growing fetus (Brosens et al., 1967; Pijnenborg et al., 1980; Lyall, 2002) . In addition to the trophoblast-mediated spiral artery remodelling, subtle changes in spiral artery structure are observed early in pregnancy in the decidua, and are termed trophoblast-independent or decidua-associated remodelling events (Harris, 2011) . Early pregnancy is associated with an influx of leukocytes into the decidua including uterine natural killer (NK) cells and macrophages. Uterine NK cells isolated from first trimester decidua secrete many angiogenic growth factors including VEGF-A, VEGF-C, PlGF and un-remodelled spiral arteries express KDR (Lash et al., 2006) . Uterine NK cells are proposed to be a major source of angiogenic growth factors at the fetal-maternal interface responsible for decidua-associated spiral artery remodelling (Hanna et al., 2006) .
The molecular mechanisms controlling spiral artery remodelling are still not clear, but it is known that during invasion, the cytotrophoblasts lose their ability to divide (Genbacev et al., 1996) and that the cells which interdigitate between maternal endothelial cells lose their epithelial characteristics and acquire an endothelial phenotype in a transition process called pseudovasculogenesis. This includes changes in the expression of cell adhesion molecules. During differentiation, cytotrophoblasts down-regulate adhesion molecules highly characteristic of epithelial cells including integrin a 6 b 4, a 5 b 6 and epithelial cadherin and up-regulate those that are expressed on endothelial cells including integrins a v b 3, a 1 b 1 , vascular endothelial cadherin, vascular cell adhesion molecule-1 (VCAM-1) and platelet endothelial cell adhesion molecule-1 (PECAM-1) (Zhou et al., 1997a, b) . These changes in cell adhesion molecules are seen only in the invasive cytotrophoblasts, suggesting that changes in the microenvironment alter gene expression (Iruela-Arispe, 1997). Integrin a v b 3 is known to play a key role in angiogenesis (Brooks et al., 1994) . VEGF-A induces endothelial cells to express increased levels of mRNA encoding a v and b 3 integrin subunits which lead to increased protein expression of a v b 3 on the endothelial cell surface. VEGF-A also induces mRNA encoding osteopontin (OPN), an a v b 3 ligand. Cell migration assays report that OPN promotes migration of microvascular endothelial cells in a concentrationdependent manner and that continuous VEGF-A stimulation, leading to increased induction of a v b 3 expression, results in increased cell migration which is inhibited by an a v b 3 neutralizing antibody (Senger et al., 1996) . VEGF-A is also known to stimulate the expression of intercellular adhesion molecule-1 and VCAM-1 in Human umbilical vein endothelial cells in vitro via activation of nuclear factor kappa B (Min et al., 2005) . These findings suggest that the VEGF family has a role in promoting trophoblast invasion and spiral artery remodelling, but more extensive studies are needed to elucidate the exact role.
VEGF family gene ablation studies
Gene ablation studies in mice have demonstrated that VEGF-A, FLT1 and Flk are crucial for embryonic angiogenesis, and homozygous gene mutations in all result in embryonic death (Table I) (Fong et al., 1995; Shalaby et al., 1995; Carmeliet et al., 1996 Carmeliet et al., , 2001 Ferrara et al., 1996) . However, VEGF-A appears to be the most critical, as embryonic lethality occurs even in the heterozygous state. PlGF does not appear to be essential for embryonic angiogenesis but can be considered a potent stimulator of this process. PlGF stimulates VEGF-A secretion by monocytes , increases VEGF-A mRNA in peripheral blood mononuclear cells (Perelman et al., 2003) and over expression of PlGF in mice results in up-regulation of FLT-1 and Flk transcription (Odorisio et al., 2002) . PlGF deficiency impairs endothelial cell response to VEGF-A, which is restored by the administration of exogenous PlGF (Carmeliet et al., 2001) . Therefore, although ineffective in being a strong angiogenic stimulator on its own, PlGF appears to amplify the effects mediated via VEGF-A. The aforementioned gene ablation studies in mice have focused on defects in embryonic angiogenesis. At present, there is a paucity of literature on the effects of VEGF family gene ablation on placental vascularization. Such studies may provide new knowledge on the role of these genes in the pathogenesis of pregnancy complications of placental origin.
Roles of the VEGF family in adverse pregnancy outcomes
The VEGF family and pre-eclampsia Pre-eclampsia is a multiorgan disorder affecting 2-7% of pregnant women leading to substantial maternal and perinatal morbidity and mortality (Sibai, 2003) . Pre-eclampsia is characterized by new onset hypertension and proteinuria after 20 weeks of gestation. In some women, it can progress to HELLP (haemolysis, elevated liver enzymes and low platelets) syndrome and eclampsia (seizures). Pre-eclampsia occurs only in the presence of the placenta (Chun et al., 1964) . Therefore, the only successful treatment remains the delivery of the placenta and hence the fetus, which may involve significant morbidity and even death of the baby in the case of early-onset pre-eclampsia.
Early placentation defects, including impaired trophoblast invasion and inadequate maternal spiral artery remodelling have been demonstrated in pre-eclampsia (Khong et al., 1986) . In vitro and in vivo studies have shown that preeclamptic placentae retain the adhesion molecules a 6 b 4, a 5 b 6 and E-Cadherin and fail to up-regulate a v b 3, a 1 b 1, Vascular endothelial cadherin, VCAM-1 and PECAM-1 which are normally expressed by the most differentiated and invasive trophoblasts (Zhou et al., 1993 (Zhou et al., , 1997a . Therefore, it is postulated that the failure of cytotrophoblasts to switch to a vascular phenotype could tip the balance of molecules that permit invasion in favour of those that restrain it, leading to a net effect of shallow endovascular invasion (Zhou et al., 1993) .
Evidence from many laboratories suggests that the absence of the normal repertoire of VEGF family members at the maternal-fetal interface may result in these deficits in cytotrophoblast differentiation observed in pre-eclampsia. Extensive studies from Susan Fisher's group have shown that cytotrophoblasts respond to the VEGF ligands they produce, and blocking the ligand binding significantly decreases their expression of integrin a 1 , and increases apoptosis. They have also shown that in severe pre-eclampsia and HELLP syndrome, VEGF-A and FLT-1 expression are decreased (Zhou et al., 2002) .
In general, studies on placental VEGF-A protein expression using immunohistochemistry have reported a decrease in VEGF-A immunostaining in pre-eclampsia (Lyall et al., 1997; Zhou et al., 2002; Cirpan et al., 2007) , severe pre-eclampsia and HELLP syndrome (Zhou et al., 2002) compared with normotensive pregnancies, while some others have reported an increase in VEGF-A protein expression in pre-eclampsia (Simmons et al., 2000; Akercan et al., 2008) .
Investigations on placental VEGF-A mRNA have shown that its level is reduced (Cooper et al., 1996; Jarvenpaa et al., 2007) VEGF family in adverse pregnancy outcomes demonstrated an increase (Chung et al., 2004) or no difference (Ranheim et al., 2001) . A recent study found placental VEGF-A mRNA to be higher in gestational hypertension, where hypertension occurs in the absence of proteinuria, but lower in pre-eclampsia with HELLP syndrome, while there was no difference in other preeclamptic placentae compared with normal placentae (Sgambati et al., 2004) . The authors propose that the high VEGF-A expression in the gestational hypetension group may be a compensatory mechanism in an attempt to restore placental blood flow to normal and that in more severe states such as in pre-eclampsia and the HELLP syndrome, there is an attempt at compensation with only some components of the placenta being able to produce VEGF-A (Sgambati et al., 2004) .
Initially, impaired invasion and spiral artery remodelling were thought to lead to defective utero-placental circulation and subsequent placental ischaemia (Brosens et al., 1972) . More recently, damage to chorionic villi by the failure of remodelling has been elegantly modelled by Burton et al., and the consequences were described (Burton et al., 2009) . True ischaemia probably only occurs in the more advanced stages of the disease. Various stressors, like oxidative stress, inflammation, and possibly even mechanical shear stress are now thought to contribute to the release of soluble factors which enter the maternal circulation inducing endothelial dysfunction leading to the clinical features of pre-eclampsia. There is considerable ongoing research on circulating factors which contribute to this maternal endothelial dysfunction. Many studies have demonstrated that increased placental expression and secretion of sFLT-1 which circulates in maternal plasma antagonises both VEGF-A and PlGF, contributing to endothelial dysfunction (Maynard et al., 2003) . Soluble FLT-1 overexpression in rats is known to result in hypertension, proteinuria and glomerular endotheliosis characteristic of pre-eclampsia (Maynard et al., 2003) . The anti-angiogenic state induced by excess placental production of sFLT-1 can be 'rescued' by administering VEGF-A and PlGF (Maynard et al., 2003) . The hypothesis that excess placental sFLT-1 may contribute to the pathogenesis of pre-eclampsia is further supported by the increased incidence of pre-eclampsia in mothers carrying trisomy 13 fetuses (Boyd et al., 1987) . The genes for sFLT-1 and FLT-1 are localized to chromosome 13. Therefore, fetuses with an extra copy of this chromosome are likely to produce more of the gene products compared with their normal counterparts (Boyd et al., 1987) . It has been shown that the ratio of circulating sFLT-1 to PlGF is significantly increased in women carrying trisomy 13 fetuses, possibly contributing to the increased risk of preeclampsia seen in these women . The molecular mechanisms leading to excess placental sFLT-1 in pre-eclampsia and the role of sFLT-1 in placentation are not yet clear. Till recently, it was believed that hypoxia was the major trigger for the release of sFLT-1 (Gu et al., 2008; Nagamatsu et al., 2004; Shore et al., 1997) , however Redman and Sargent recently hypothesized that the primary placental defect that triggers pre-eclampsia is likely to be oxidative stress rather than hypoxia. They propose that this inflammatory stimulus provokes the release of sFLT-1 to a similar or greater extent than hypoxia (Redman and Sargent, 2009) . Recently, four splice variants of sFLT-1 were also discovered, of which three are known to be up-regulated in preeclamptic placentae (Heydarian et al., 2009) . The sFLT-14 variant which has anti-angiogenic effects similar to sFLT-1 is primate specific and is known to be up-regulated in syncytial knots in preeclamptic placentae (Sela et al., 2008) .
There is consistent evidence that placental expression (Zhou et al., 2002; Maynard et al., 2003; Tsatsaris et al., 2003) and maternal serum (Tsatsaris et al., 2003; Hertig et al., 2004; Levine et al., 2004) sFLT-1 are increased in preeclamptic women compared with normal pregnant women. While the majority of studies have demonstrated that there is no significant difference in maternal serum sFLT-1 levels prior to 20 weeks of gestation in women who develop pre-eclampsia compared with normal pregnancies (McKeeman et al., 2004 ), a few studies have shown a significant difference prior to 20 weeks (Table II) . In women who subsequently develop pre-eclampsia, maternal serum sFLT-1 levels are known to rise at 20 weeks of gestation and the levels are significantly increased 5 weeks prior to the onset of hypertension and proteinuria ). The sFLT-1 level is observed to be directly proportional to the degree of proteinuria (Chaiworapongsa et al., 2004) and in preeclamptic women, the concentration is known to be higher in those with earlier onset disease (Chaiworapongsa et al., 2004; Levine et al., 2004) , or severe disease (Maynard et al., 2003; Chaiworapongsa et al., 2004; Levine et al., 2004) and in those who deliver small-for-gestational-age infants Shibata et al., 2005) .
Maternal serum PlGF is known to be the reciprocal of sFLT-1; the higher the sFLT-1, the lower the PlGF . During normal pregnancy, there is a steady increase in serum PlGF during the first two trimesters, a peak at 29 -32 weeks and a decline thereafter (Taylor et al., 2003; Levine et al., 2004) . In women who subsequently develop pre-eclampsia, serum PlGF concentrations are lower as early as 10 -13 weeks of gestation (Su et al., 2001; Tidwell et al., 2001; Polliotti et al., 2003; Taylor et al., 2003; Bersinger and Odegard 2004; Krauss et al., 2004; Levine et al., 2004; Thadhani et al., 2004; Akolekar et al., 2008 ) with a considerable diminution 5 weeks prior to the clinical onset of the disease . Serum PlGF levels at 21 -32 weeks of gestation are known to be lower in early pre-eclampsia (prior to 37 weeks) compared with late onset, severe disease compared with mild disease and in pre-eclampsia associated with a small-for-gestational-age infant compared with an appropriate size for gestational age infant Madazli et al., 2005) . Urinary PlGF is known to parallel the serum level with a rise in the first two trimesters, reaching a peak at 29 -32 weeks and a steady decline thereafter. In preeclamptic women, the pattern is similar but substantially lower (Aggarwal et al., 2006) with the most pronounced difference observed 5 weeks prior to the clinical onset of the disease (Levine et al., 2005) . The development of pre-eclampsia, however, is not preceded by altered urinary PlGF in the first trimester of pregnancy (Savvidou et al., 2009) .
Current evidence suggests that low circulating PlGF and high circulating sFLT-1 early (11 -13 weeks) and in mid-pregnancy can distinguish women who subsequently develop pre-eclampsia from those who remain normotensive throughout pregnancy (Table II) . It has also been demonstrated that an algorithm that uses PlGF in combination with other markers (Chappell et al., 2002; Espinoza et al., 2007; Stepan et al., 2007; Akolekar et al., 2008; Kusanovic et al., 2009; Poon et al., 2009 Poon et al., , 2010 Yu et al., 2010; Akolekar et al., 2011) or the sFLT-1/PlGF ratio (Moore Simas et al., 2007; De Vivo et al., 2008; Diab et al., 2008; Lim et al., 2008 ) is a better screening tool than either PlGF or sFLT-1 used on their own (Table II) Although VEGF-A plays an important role in normal pregnancy and in the pathogenesis of pre-eclampsia, maternal serum VEGF-A has a limited clinical role in the prediction of pre-eclampsia. Soluble FLT-1 binds VEGF-A with a higher affinity than PlGF, resulting in extremely low circulating levels of free VEGF-A. A few studies have reported reduced serum VEGF-A in pre-eclampsia (Reuvekamp et al., 1999) and have proposed VEGF-A as a promising marker for prediction of severe, early-onset pre-eclampsia (Polliotti et al., 2003) , but others have failed to observe this due to the concentration being below the detection level of currently available ELISA kits (Taylor et al., 2003; Thadhani et al., 2004; Akolekar et al., 2010) . Contrary to the theory of reduced serum VEGF-A in pre-eclampsia, several investigators have shown that maternal serum VEGF-A is increased in preeclamptic pregnancies compared with normotensive pregnancies (Baker et al., 1995; Kupferminc et al., 1997; Hunter et al., 2000; Bosio et al., 2001) . This discrepancy is believed to be due to the type of VEGF-A measured. It is proposed that total serum VEGF-A may be increased in preeclamptic pregnancies and that the free level is reduced due to binding to sFLT-1. VEGF-A is produced by many cells at the maternal -fetal interface. A recent study demonstrated that the proportions of VEGF-A expressing peripheral blood T and NK cells were markedly decreased in preeclamptic women compared with healthy pregnancies, suggesting that the reduced maternal serum VEGF-A is not only the result of antagonism by sFLT-1 (Molvarec et al., 2010) .
The strong evidence supporting the use of PlGF and sFLT-1 as predictive screening tests for pre-eclampsia has led to these biomarkers being validated for routine clinical use in some countries. However, extensive studies have demonstrated that these biomarkers are more predictive of early-onset pre-eclampsia and severe preeclampsia, and that the highest predictive values are demonstrated during second trimester screening (Table II) . Therefore, although maternal serum and urinary angiogenic proteins provide a strong predictive tool for a subset of preeclamptic women, they have a limited role in prediction of intermediate and late pre-eclampsia. Furthermore, for intervention to be successful, an early screening tool would be of more utility than a second trimester test.
Recently, the potential use of the VEGF family in the treatment of pre-eclampsia has also been explored. Li and colleagues describe a pre-eclampsia model in pregnant rats induced by adenoviral overexpression of sFLT-1 (Adv-sFLT-1). Infection with Adv-sFLT-1 in rats resulted in hypertension and proteinuria. Histologically, the kidneys from these rats showed glomerular endotheliosis, reminiscent of the renal lesions associated with pre-eclampsia in pregnant women. Administration of recombinant VEGF-A 121 resulted in a reduction in systolic blood pressure and proteinuria and an improvement in glomerular endotheliosis (Li et al., 2007) . Similar findings have been reported in other animal models (Gilbert et al., 2010; Mateus et al., 2011; Woods et al., 2011) , suggesting that VEGF-A 121 may have a therapeutic potential in the management of pre-eclampsia. In a mouse model of pre-eclampsia, treatment with either VEGF-A 164 or PlGF-2 was shown to reduce the blood pressure, but proteinuria was unaffected by either treatment (Suzuki et al., 2009) . These findings provide interesting insights into the potential role of VEGF-A and PlGF in the management of pre-eclampsia. Future studies focusing on the possible adverse effects of VEGF therapy on the fetus and the placenta will be beneficial.
The VEGF family and SGA neonates
Being born SGA significantly increases the risk for neonatal complications and is a leading cause of perinatal death (de Courcy-Wheeler et al., 1995; Tenovuo, 1988) . SGA is also associated with impaired neural development and cognition demonstrated by lower intelligence, poor academic performance and behavioural abnormalities in childhood (Pryor et al., 1995; McCormick et al., 1996; Grantham-McGregor, 1998) , as well as a lower academic achievement in adulthood (Strauss, 2000) . A consistent association has also been demonstrated between SGA and adult onset diseases including increased risk for developing coronary artery disease, stroke, hypertension and type 2 diabetes mellitus (Barker et al., 1989 (Barker et al., , 1990 McKeigue et al., 1998; McMillen and Robinson, 2005) . Those born with low birthweight (LBW) are known to develop endothelial dysfunction, which is an early event in atherosclerosis, which becomes apparent in childhood (Leeson et al., 1997) and persists into adulthood when additional cardiovascular risk factors start to play a role in vascular pathology (Leeson et al., 2001) .
The majority of SGA babies are born to normotensive mothers (81.7%), but some are born to women with pre-eclampsia (10.7%) or gestational hypertension (7.6%) (Groom et al., 2007) . Pregnancies complicated by SGA caused by placental vasculopathy share many pathogenic abnormalities with pre-eclampsia. In addition, SGA pregnancies also demonstrate maternal endothelial cell dysfunction (Friedman et al., 1994; Bretelle et al., 2001; Johnson et al., 2002) and leukocyte activation (Sabatier et al., 2000) .
Some studies report that maternal serum PlGF levels are lower in normotensive women with SGA infants as early as first trimester of pregnancy compared with gestational age-matched controls Erez et al., 2008; Poon et al., 2008; Romero et al., 2008; Karagiannis et al., 2010) . Others, however, report no significant difference between SGA and controls early in gestation but significant different levels later in gestation. A longitudinal study examining PlGF concentration in pregnant women at ,14, 15 -19, 21 -25, 27-30, 35-38 weeks gestation has shown a lower level of PlGF approaching significance at 27-30 weeks in normotensive women delivering an SGA infant compared with normotensive controls, but did not observe any difference earlier in gestation (Taylor et al., 2003) . Another study reported that maternal serum PlGF levels in normotensive women with SGA infants were significantly lower than gestational age-matched controls at 33 weeks but not at 17 or 25 weeks (Bersinger and Odegard, 2004) . Urinary PlGF during mid-pregnancy has not been shown to be affected by the presence of an SGA infant (Levine et al., 2005) .
As with PlGF, several studies have investigated sFLT-1 in normotensive pregnancies with SGA infants compared with matched controls. Some report maternal serum sFLT-1 to be increased in normotensive women who deliver a SGA infant at term (Tsatsaris et al., 2003; Wallner et al., 2007) but others report no difference at term (Shibata et al., 2005) or in the second (Wathen et al., 2006) or first trimester . A longitudinal study evaluating sFLT-1 at 4 week intervals from the first antenatal clinic visit until delivery has shown no difference in maternal serum sFLT-1 levels in normotensive women destined to deliver a SGA infant compared with controls .
A recent large study of 1536 SGA and 31 314 non-SGA pregnancies reported that using a combination of maternal characteristics with mean arterial pressure, uterine artery pulsatility index, fetal nuchal translucency thickness, pregnancy-associated plasma protein-A (PAPP-A), free b-hCG, PlGF, placental protein-13 (PP13) and a disintegrin and metalloprotease can detect SGA in the absence of preeclampsia at 11 -13 weeks. The detection rates in this study were 73% for SGA requiring delivery before 37 weeks and 46% for those delivering at term (Karagiannis et al., 2010) .
Drawing overall conclusions on the predictive value of VEGF family on SGA pregnancies is hampered by the widespread practice of using different definitions to diagnose SGA, as well as the use of the terms SGA and IUGR (intrauterine growth restriction) synonymously.
The VEGF family and IUGR
IUGR remains a major challenge in pregnancy but lacks a precise definition. IUGR results from many causes including congenital abnormalities, infections and substance abuse. However, most cases of IUGR are associated with placental insufficiency (Lackman et al., 2001) . Umbilical, and to a lesser extent uterine, artery Doppler are used as surrogate markers to evaluate placental function and to diagnose IUGR.
Studies using umbilical or uterine artery Doppler in identifying IUGR in the absence of maternal hypertensive disease show that maternal serum sFLT-1 is increased in these pregnancies compared with pregnancies of normotensive women delivering average for gestational age infants (Stepan et al., 2004 (Stepan et al., , 2007 Crispi et al., 2006; Savvidou et al., 2006; Wallner et al., 2007; Chaiworapongsa et al., 2008a, b) . A recent study reported that there was no difference in mean maternal plasma sFLT-1 between normotensive women who delivered an SGA infant compared with matched controls, but that a significant increase was only seen in a subset of women who had an abnormal uterine artery Doppler and delivered an SGA infant (Chaiworapongsa et al., 2008a, b) . This study also demonstrated that the magnitude of the increase of sFLT-1 was related to the Doppler abnormalities in the maternal and fetal vasculatures, suggesting that oxidative stress and shear stress may contribute to the increase in sFLT-1 in the maternal circulation (Burton and Jauniaux, 2004; Chaiworapongsa et al., 2008a, b) . A study that measured maternal plasma PlGF and sFLT-1 in the second trimester in a subgroup of women with abnormal uterine perfusion revealed that concurrent measurement of uterine perfusion with angiogenic proteins allows effective prediction of early onset IUGR. However, a strong predictive value was not detected for overall IUGR (Table III) (Stepan et al., 2007) .
From the above findings, it appears that studies of predictive markers for IUGR pregnancies have demonstrated more consistent results compared with those for SGA pregnancies. However, at present, there are insufficient data to recommend the VEGF family angiogenic growth factors as reliable biomarkers for the prediction of SGA or IUGR pregnancies.
Soluble KDR in pre-eclampsia and SGA
The soluble form of the KDR receptor (sKDR) has been detected in human plasma (Ebos et al., 2004) and the recombinant form of this protein has been shown to have anti-angiogenic activity (Agostini et al., 2005) . Maternal plasma sKDR is known to be reduced in pre-eclampsia and in growth-restricted pregnancies (Wallner et al., 2007) . In a cross-sectional study, plasma sKDR was analysed in four groups; non-pregnant women, women with an uncomplicated pregnancy, preeclamptic women and non-preeclamptic women who delivered an SGA infant. There was no significant difference in mean plasma sKDR between non-pregnant women and women with uncomplicated pregnancies. Preeclamptic women, as well as non-preeclamptic women with SGA infants, were shown to have lower mean plasma sKDR compared with women with uncomplicated pregnancies. There was no significant difference in mean plasma sKDR between preeclamptic women and non-preeclamptic women with SGA infants (Chaiworapongsa et al., 2008a, b) . Interestingly, no significant difference was observed in plasma sKDR concentration between SGA with and without abnormal uterine artery Doppler, indicating that utero-placental ischaemia may not be a major determinant of plasma sKDR (Chaiworapongsa et al., 2008a,b) . In contrast to the above study, one study reported that there was no difference in maternal plasma sKDR levels in preeclamptic women compared with women with uncomplicated pregnancies, however, the small sample size in this study may have yielded insufficient statistical power to detect a difference (Masuyama et al., 2006) . VEGF-A is known to mediate most of its actions via the membranebound KDR receptor. The role of sKDR in VEGF-A signalling is yet to be determined. However, sKDR is known to have anti-angiogenic properties. The administration of adenovirus encoding murine sKDR to non-pregnant rats induces hypertension and proteinuria, but this effect is not seen in pregnant rats. The high levels of unopposed PlGF produced by the placenta in the pregnant rat may explain these findings (Maynard et al., 2003) . Reduced maternal plasma sKDR in pre-eclampsia and SGA compared with uncomplicated pregnancies is unexpected, given that pre-eclampsia and, to a lesser extent, SGA are considered anti-angiogenic conditions. While it is still not clear what biological factors contribute to the expression of sKDR, the expression of the membranous isoform of KDR is stimulated by VEGF-A (Shen et al., 1998) . Therefore, it was proposed that the low sKDR in pre-eclampsia and SGA could possibly result from low availability of free VEGF-A to stimulate KDR on endothelial cells (Reuvekamp et al., 1999; Maynard et al., 2003; Chaiworapongsa et al., 2008a, b) . At present, very few studies have evaluated the role of sKDR in normal and complicated pregnancies and future research is needed to validate the results.
Soluble endoglin in pre-eclampsia
Although not a member of the VEGF family, soluble endoglin (sEng), in combination with PlGF and sFLT-1, may be useful in prediction of pre-eclampsia. Endoglin (CD 105) is a transmembrane glycoprotein predominantly expressed on endothelial cells. It is a co-receptor for TGF-b 1 and TGF-b 3 (Cheifetz et al., 1992) . Endoglin modulates signalling of TGF-b by interacting with TGF-b receptors I and II (Fonsatti and Maio, 2004) . Endoglin regulates nitric oxide-dependent vasodilatation (Jerkic et al., 2004) and its expression is up-regulated in tissues undergoing angiogenesis (Fonsatti and Maio, 2004) . Endoglin gene mutations are associated with hereditary haemorrhagic telangiectasia type 1, a vascular disorder characterized by focal telangiectases and arteriovenous malformations (Lebrin and Mummery, 2008) . These suggest the involvement of endoglin in angiogenesis, vascular development and in maintaining vessel wall integrity (Fonsatti and Maio, 2004) . Proteolytic processing of the membrane-bound endoglin results in sEng, an N-terminal cleavage product of the full-length endoglin (Venkatesha et al., 2006) . In vitro studies have demonstrated that sEng inhibits TGF-b signalling, blocks TGF-b-mediated vasodilatation and interferes with endothelial proliferation and capillary formation (Venkatesha et al., 2006) . Endoglin deficiency does not affect vasculogenesis but results in poor vascular smooth muscle development and arrested endothelial remodelling, and endoglin is shown to be essential for angiogenesis (Li et al., 1999) . sEng is also implicated in the pathophysiology of pre-eclampsia.
Placental expression of sEng is up-regulated in pre-eclampsia. It is proposed that sEng enters the maternal circulation and inhibits TGF-b signalling resulting in endothelial dysfunction (Venkatesha et al., 2006) . Over-expression of sEng in rodents leads to increased vascular permeability and hypertension without proteinuria, and over-expression of both sEng and sFLT-1 results in severe vascular damage, nephrotic-range proteinuria, severe hypertension, a syndrome similar to HELLP syndrome and IUGR (Venkatesha et al., 2006) . Maternal serum sEng concentrations increase during the last 2 months of normal pregnancy and this rise is higher and occurs earlier in women who develop pre-eclampsia. The increase in sEng is associated with an increase in the ratio of sFLT-1: PIGF and a composite measure incorporating all three molecules, the ratio of (sFLT-1+ sEng): PIGF, is considered a predictive biomarker for pre-eclampsia .
The VEGF family and preterm birth
Preterm deliveries are those that occur before the completion of 37 weeks of gestation. In developed countries, the rate of preterm birth is 5-9% and as much as 12% in the USA (Goldenberg et al., 2008) . Preterm birth contributes to 75% of perinatal mortality and increases long-term morbidity (McCormick, 1985) . In addition to the immediate complications during the neonatal period, those born preterm are at increased risk for neuro-developmental and behavioural disorders in childhood and cardiovascular disorders and type 2 diabetes in adult life (Saigal and Doyle, 2008) . Preterm birth is clinically categorized as (i) spontaneous preterm birth, which follows (a) preterm labour with intact membranes or (b) preterm premature rupture of membranes (PPROMs), or (ii) indicated preterm birth, in which labour is either induced or the infant is delivered by pre-labour Caesarean section for maternal or fetal reasons which include, among other conditions, maternal pre-eclampsia, eclampsia, haemorrhage and fetal non-reassuring heart rate and IUGR (Goldenberg et al., 2008) . Spontaneous preterm labour is known to be initiated by many factors including intrauterine infection, inflammation, uteroplacental ischaemia or haemorrhage, uterine over-distension, stress and other immunological processes (Romero et al., 1994 .
The most common types of placental pathology seen in spontaneous preterm birth include infection, inflammation and infarction/ haemorrhage (Faye-Petersen, 2008) . Recently, a failure in maternal spiral artery remodelling was reported in patients with preterm labour and intact membranes as well as in those with PPROMs (Kim et al., 2002 (Kim et al., , 2003 . In the group with preterm labour with intact membranes, the mean percentage of spiral arteries with failure of physiological transformation in the myometrial and decidual segments was shown to be significantly higher than in normal pregnant women at term (Kim et al., 2003) . In the group with PPROMs, similar results were shown, but the defect was confined to the myometrial segments of the spiral arteries (Kim et al., 2002) .The mechanisms responsible for this failure of physiological transformation have not yet been determined. A possible mechanism is the inability of trophoblasts to downregulate cell adhesion molecules characteristic of epithelial cells and to up-regulate those characteristic of endothelial cells (Zhou et al., 1997a,b) .
At present, data from clinical studies on the role of VEGF family in preterm birth are limited. One large study of 292 women with spontaneous preterm birth and 937 controls analysed PlGF and sFLT-1 in maternal serum collected between 10 and 14 weeks of gestation. This study did not find any association between early PlGF levels and subsequent preterm birth. However, women with higher circulating sFLT-1 at 10 -14 weeks of gestation were at a lower risk of spontaneous preterm birth (Smith et al., 2007) . The biological basis of this finding is yet to be determined. It has been shown that VEGF-A is expressed in the myometrium of the pregnant human uterus (Oh et al., 2006) . In pregnant rats, VEGF-A, FLT-1 and Flk are expressed in the cervix and VEGF-A expression is known to peak in association with ripening of the cervix (Mowa et al., 2004) . Therefore, it is proposed that low sFLT-1 resulting in increased free VEGF-A may promote preterm birth (Smith et al., 2007) . Hence, it is plausible that high sFLT-1 could have a protective role in preterm birth. However, a recent study revealed that in the setting of inflammation (elevated high sensitivity C-reactive protein), women with low serum PlGF levels at the time of onset of spontaneous preterm labour had a 6.8-fold increased risk of preterm birth (Bastek et al., 2010) . These findings suggest an interaction between the angiogenic and inflammatory pathways which merits future research.
The VEGF family and recurrent pregnancy loss Spontaneous pregnancy loss affects 12 -15% of couples (Stirrat, 1990) and 0.5-3% experience recurrent pregnancy loss defined as the occurrence of three or more consecutive pregnancy losses (Li et al., 2002) . There is increasing evidence that there is no significant difference in the possible causes between those who experience two compared with three miscarriages (Habayeb and Konje, 2004) and it is recommended that couples should be investigated after two miscarriages (Quenby and Farquharson, 1993; Stephenson et al., 1998) . Parental chromosome abnormalities (Houwert-de Jong et al., 1989), uterine defects (Houwert-de Jong et al., 1989), thrombophilias (Habayeb and Konje, 2004; Kist et al., 2008) , anti-phospholipid syndrome (Habayeb and Konje, 2004) , endocrinological disorders, infections and nutritional and environmental factors (Li et al., 2002 ) have all been documented as possible causes for recurrent miscarriage. However, in 50% of recurrent pregnancy loss, the cause remains unknown (Li et al., 2002; Habayeb and Konje, 2004) .
The majority of spontaneous miscarriage occurs during the first trimester of pregnancy. Blighted ovum, the most common type of first trimester miscarriage, is mostly associated with aneuploidy. With regard to defective placentation as a cause of early miscarriage, it should be noted that remodelling of spiral arteries in the decidual segments is well established by 8 weeks of gestation and is completed by the end of the first trimester (Pijnenborg et al., 1980) . However, failed trophoblast invasion and spiral artery remodelling are not demonstrated in early miscarriage (Ball et al., 2006a, b) . In contrast to this, late sporadic miscarriage which occurs after 12 weeks of gestation and complicates 1-2% of pregnancies (Regan and Rai, 2000) does exhibit abnormalities in spiral artery transformation and trophoblast invasion (Ball et al., 2006a, b) .
VEGF-A, PlGF and the main receptors KDR and FLT-1 are known to regulate decidual vascularization in early human pregnancy (Plaisier et al., 2007) . Decidual vascularization is shown to be different in first trimester spontaneous miscarriages compared with matched controls. Decidual samples from miscarriage show fewer vessels with larger circumferences in both decidua basalis and decidua parietalis compared with those obtained from first trimester terminations and these vascular differences correlate with increased expression of KDR and FLT-1 (Plaisier et al., 2009) . In contrast, a higher vessel density in the decidua parietalis (Vailhe et al., 1999) and decreased VEGF-A and FLT-1 are reported in missed abortions (Vuorela et al., 2000) .
In addition to post-implantation pregnancy loss, 30% of spontaneously conceived embryos are lost prior to implantation and .50% of embryos conceived through IVF fail to implant (Boomsma et al., 2009) . In humans, the ability of the conceptus to implant in the endometrium is restricted to a few days in the menstrual cycle. This window of implantation minimises the risk of late implantation of compromised embryos . Differentiation of endometrial stromal cells into specialized decidual cells, termed decidualization, is critical for the endometrium to achieve the characteristics essential to recognize, respond to and eliminate compromised implanting embryos . A recent paper by Dr Jan Brosen's group demonstrates that impaired cyclic decidualization of the endometrium facilitates implantation yet predisposes to subsequent pregnancy loss by disabling natural embryo selection and by disrupting the maternal response to embryonic signals . Intrauterine VEGF-A levels are known to be cycle dependant with increasing levels during the late-secretory phase shown to be correlated with decidualization (Licht et al., 2003) . A positive correlation is also shown between intrauterine VEGF-A levels and the decidualization marker IGF-binding protein (IGFBP)-1 (Licht et al., 2003) . There is a sharp rise in intrauterine IGFBP-1 levels coinciding with the time of the closing of the implantation window, suggesting that intrauterine IGFBP-1 may be involved in the mechanisms restricting endometrial receptivity (Licht et al., 2002) . Although correlations do not necessarily reflect causality, it could be hypothesized that low intrauterine VEGF-A levels may have a role in impaired decidualization and prolonged endometrial receptivity in recurrent pregnancy loss.
VEGF family gene polymorphisms and adverse pregnancy outcomes
The VEGF family plays a pivotal role in normal pregnancy, and consistent evidence exists for its causal role in pregnancy complications. Therefore, genetic variations in the genes encoding these angiogenic proteins have been good candidates to study in pregnancy complications (Table IV) .
VEGF family polymorphisms in pre-eclampsia
Several groups have studied functional VEGF-A polymorphisms in preeclampsia. The VEGF-A +936C/T polymorphism is in the 3 ′ untranslated region (3 ′ UTR) of the VEGF-A gene and the T allele is associated with lower plasma VEGF-A compared with the C allele (Renner et al., 2000) . Two groups report the association of the VEGF-A+ 936C/T polymorphism with pre-eclampsia. A Korean study reports the association of the maternal VEGF+936T allele with pre-eclampsia (Shim et al., 2007) , while a Greek study reports no association of the maternal polymorphism with pre-eclampsia, but found an association of the T allele with severe pre-eclampsia. However, their study sample was relatively small and the severe preeclamptic group comprised only 20 women (Papazoglou et al., 2004b) . The VEGF-A+405G/C is a promoter polymorphism and the GG genotype is associated with the highest plasma VEGF-A levels Stevens et al., 2003) . The G allele of this polymorphism is shown to be associated with a reduced risk for severe pre-eclampsia (Banyasz et al., 2006a, b) while the CC genotype is shown to be associated with an increased risk for HELLP syndrome (Nagy et al., 2008) . The VEGF-A 2460C/T promoter polymorphism is in linkage disequilibrium with the +405G/C polymorphism and the TT genotype is shown to be associated with an increased risk for the HELLP syndrome (Nagy et al., 2008) . The VEGF-A 22578C/A is a promoter polymorphism with the CC genotype having the highest transcriptional activity and VEGF-A protein production by leukocytes (Shahbazi et al., 2002) . Four groups have studied this polymorphism and report no association with pre-eclampsia (Papazoglou et al., 2004b; Sandrim et al., 2009) , severe pre-eclampsia (Banyasz et al., 2006a, b) or the HELLP syndrome (Nagy et al., 2008) . However, Banyasz reported that hypertension and proteinuria were detected earlier in carriers of the VEGF-A-2578C/A A allele in their population of severe preeclamptic women (Banyasz et al., 2006a, b) . Sandrim et al. (2009) also report that when stratified by ethnicity, the AA genotype of the VEGF-A 22578C/A polymorphism was less common in preeclamptic white women compared with healthy pregnant controls.
The VEGF-A 2634G/C and 21154G/A polymorphisms are located in the 5 ′ untranslated region (5 ′ UTR) of the VEGF-A gene and the 2634C and 21154G alleles are associated with higher VEGF-A production (Awata et al., 2002; Shahbazi et al., 2002) . Both polymorphisms have been studied in pre-eclampsia and no association is reported (Papazoglou et al., 2004b; Sandrim et al., 2009) . However, in the study by Sandrim et al., the GG genotype of the VEGF-A 2634G/C polymorphism is reported to be significantly less common in the white preeclamptic women compared with controls. At present, genetic association studies on the above polymorphisms are limited by the sample size. A meta-analysis was deemed inappropriate due to the phenotypic differences in the preeclamptic study populations.
A recent large study evaluated 112 tagging polymorphisms in VEGF-A, VEGF-B, VEGF-C, FLT1 and FLT4 in white and black preeclamptic women with matched controls. This study reported the association of polymorphisms in VEGF-C and FLT1 genes in either white and black preeclamptic women, but did not find the same polymorphism to be associated with pre-eclampsia in both ethnic groups. This may be partially explained by ethnic differences in the distribution of these polymorphisms and the relatively small group of white preeclamptic women in the study (Srinivas et al., 2010) .
A dinucleotide repeat polymorphism in the 3 ′ non-coding region of the FLT1 gene has also been studied in preeclamptic Korean women, with no association reported . In a preliminary study, we recently demonstrated that homozygosity for the C allele of the KDR 2604C/T polymorphism in both the father and the infant was associated with pre-eclampsia. KDR 2604T/C is a promoter polymorphism with the C allele exhibiting 68% lower transcriptional activity compared with the T allele and the CC homozygotes having significantly lower KDR levels compared with TT homozygotes (Wang et al., 2007) . The KDR 2604T/C polymorphism has previously been shown to be associated with coronary artery disease, hence the association with pre-eclampsia is interesting, but needs to be replicated in a larger cohort (Andraweera et al., 2012) .
VEGF family polymorphisms in SGA infants
At present, literature on the role of VEGF family polymorphisms in SGA is limited. VEGF-A +405G/C and 22578C/A polymorphisms have been studied in a group of LBW infants compared with term healthy controls. The C allele of the +405G/C polymorphism is associated with an increased risk for LBW infants (Banyasz et al., 2006a, b) .
The VEGF-A 22578C/A polymorphism was not associated with LBW but the A allele was associated with increased risk for necrotizing enterocolitis and a decreased risk for acute renal failure during the perinatal period.
In our preliminary study mentioned above, we also demonstrated that the KDR +604C/T polymorphism in both the father and the infant was associated with SGA as well as SGA with an abnormal Doppler (Andraweera et al., 2012) . In addition, our group recently demonstrated that the VEGF-A +936C/T polymorphism in the infant was associated with SGA as well as SGA with an abnormal Doppler. We also found that the polymorphism in both the mother and the infant was associated with uterine and umbilical artery Doppler abnormalities and that the polymorphism in the first trimester placenta was associated with reduced first trimester placental VEGF-A mRNA expression, suggesting a potential role of this SNP in the pathogenesis of SGA (Andraweera et al., 2011) .
VEGF family polymorphisms in preterm birth
Only one study has so far looked at VEGF SNPs in spontaneous preterm birth; it reported an increased frequency of the VEGF-A +936C/T T allele in women who experienced spontaneous preterm birth compared with controls, but no association for the VEGF-A 2634G/C polymorphism (Papazoglou et al., 2004a) .
VEGF family polymorphisms in recurrent pregnancy loss
The VEGF-A polymorphisms, 21154G/A, 22578C/A, +936C/T and 2634G/C have been studied in women who have experienced recurrent pregnancy loss in a few ethnic groups.
The VEGF-A 21154G/A polymorphism has been investigated in six studies of which three reported the association of the A allele with an increased risk for recurrent miscarriage (Papazoglou et al., 2005; Coulam and Jeyendran, 2008; Lee et al., 2010) and the other three reported no association (Eller et al., 2011a, b; Su et al., 2011a, b; Xing et al., 2011) .
The VEGF-A 2578C/A, +936C/T and 2634G/C polymorphisms have not been associated with recurrent pregnancy loss (Papazoglou et al., 2005; Lee et al., 2010; Traina et al., 2011) , except in a recent study which reported a decreased frequency of the VEGF-A 22578A allele and an increased frequency of the VEGF-A 2634C allele in recurrent pregnancy loss (Eller et al., 2011b) .
Of these polymorphisms, a recent meta-analysis demonstrated that the VEGF-A 21154G/A polymorphism was significantly associated with recurrent pregnancy loss (odds ratio (OR), 1.5; 95% confidence interval, 1.122.0) (Su et al., 2011a) .
Conclusions regarding VEGF family polymorphisms
Overall, these candidate gene association studies demonstrate that polymorphisms in the VEGF family of angiogenic growth factors appear to be implicated in pregnancy complications. However, the effect of these polymorphisms on adverse pregnancy outcomes appears to be small as evidenced by the reported ORs. The repeatability of the results is also poor across different ethnic groups. Therefore, polymorphisms in the VEGF family genes explored so far do not appear to have a role in the clinical prediction of adverse pregnancy outcomes. Considering the important environmental and lifestyle modifiable risk factors for pregnancy complications, it will be interesting to investigate potential gene -gene and gene-environment interactions in the VEGF family genes.
Discussion
Recent years have seen considerable advances in the role of the VEGF family in pregnancy complications, mainly in pre-eclampsia. Extensive studies by Ananth Karumanchi's group have clearly demonstrated that the anti-angiogenic factors sFLT-1 and sEng play important roles in the pathophysiology of pre-eclampsia. These findings have been replicated in later years by other groups showing consistent evidence. Several prospective cohort studies have demonstrated that serum/ plasma levels of PlGF, sFLT-1, sEng and the sFLT-1/PlGF ratio may be useful biomarkers in the prediction of pre-eclampsia, although they may not be useful sufficiently early in gestation to permit intervention. The reviewed literature also demonstrates that these biomarkers in combination with other clinical and biochemical investigations are better at predicting pre-eclampsia than when used alone. The deviation of the plasma/serum levels of these biomarkers from normal reference ranges are more pronounced in women with earlier onset pre-eclampsia, while the deviation is minimal in those who develop late-onset pre-eclampsia. Therefore, the clinical utility of these biomarkers is limited to a subset of women. Ohkuchi et al. (2011) recently proposed that these findings suggest the existence of thresholds for the onset of pre-eclampsia and set out to determine the thresholds for plasma concentrations of angiogenic (PlGF) and anti-angiogenic (sFLT-1 and sEng) factors at the onset of pre-eclampsia. The authors report that these thresholds exist for sFLT-1 and sFLT-1/ PlGF ratio, and the threshold for sFLT-1/PlGF ratio measured between 26 and 31 weeks of gestation may be useful for detecting pre-eclampsia with onset at ,36 weeks. Consistent with previous studies, the authors also report that consideration of established maternal risk factors in the algorithm increases the likelihood ratios of the prediction model. The onset threshold levels of sFLT-1 and sFLT-1/ PlGF ratio at an earlier gestational age were very high and deviated markedly from the reference ranges, suggesting a possible reason for the lower incidence of early-onset pre-eclampsia compared with late onset disease.
Endothelial dysfunction has long been recognized to play a key role in the pathophysiology of pre-eclampsia. However, most studies on prediction of pre-eclampsia have not incorporated measures of endothelial function into the predictive algorithms. Maternal endothelial function is shown to be markedly altered before the onset of clinical features of pre-eclampsia (Khan et al., 2005) . Therefore, inclusion of non-invasive measures of endothelial function may improve the predictive value of these models (Banek and Gilbert, 2011) .
Maternal endothelial dysfunction in pre-eclampsia is mainly attributed to defective placentation. However, there is increasing evidence to suggest that abnormal placentation may not be the sole reason for altered endothelial function in preeclamptic women (Chambers et al., 2001; Kaaja and Greer, 2005) . A history of pre-eclampsia, as well as delivery of a growth-restricted baby, is associated with increased long-term risk for vascular diseases including coronary artery disease and stroke (McDonald et al., 2008) . It is debatable as to whether endothelial dysfunction manifests as a consequence of these pregnancy complications and persists throughout life or whether women with risk factors for endothelial dysfunction manifest these vascular diseases at different stages. The shared risk factors for both pre-eclampsia and later-life vascular diseases, as well as the familial segregation of all these disorders suggest that these diseases share a common genetic predisposition that interacts with the environment and may predispose individuals to vascular disorders which manifest at different time points throughout the life course.
Prospective cohort studies with the aim of collecting data on relevant clinical, environmental and lifestyle risk factors coupled with longitudinal measurement of angiogenic factors, endothelial function and genetic variations in candidate gene pathways will be beneficial in establishing interactions which predispose to pregnancy complications.
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